These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23687087)

  • 1. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
    Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
    Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
    Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
    J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.
    Wang J; Liu Y; Li Z; Du J; Ryu MJ; Taylor PR; Fleming MD; Young KH; Pitot H; Zhang J
    Blood; 2010 Dec; 116(26):5991-6002. PubMed ID: 20921338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
    Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
    J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.
    Wang J; Liu Y; Tan LX; Lo JC; Du J; Ryu MJ; Ranheim EA; Zhang J
    Cell Cycle; 2011 Sep; 10(17):2836-9. PubMed ID: 21857161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.
    Li Q; Bohin N; Wen T; Ng V; Magee J; Chen SC; Shannon K; Morrison SJ
    Nature; 2013 Dec; 504(7478):143-147. PubMed ID: 24284627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
    Wang J; Liu Y; Li Z; Wang Z; Tan LX; Ryu MJ; Meline B; Du J; Young KH; Ranheim E; Chang Q; Zhang J
    Blood; 2011 Jul; 118(2):368-79. PubMed ID: 21586752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
    Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
    Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.
    Kunimoto H; Meydan C; Nazir A; Whitfield J; Shank K; Rapaport F; Maher R; Pronier E; Meyer SC; Garrett-Bakelman FE; Tallman M; Melnick A; Levine RL; Shih AH
    Cancer Cell; 2018 Jan; 33(1):44-59.e8. PubMed ID: 29275866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic N-Ras Mitigates Oxidative Stress-Induced Apoptosis of Hematopoietic Stem Cells.
    Ney GM; Yang KB; Ng V; Liu L; Zhao M; Kuk W; Alaka L; Sampang L; Ross A; Jones MA; Jin X; McKay LM; Evarts H; Li Q
    Cancer Res; 2021 Mar; 81(5):1240-1251. PubMed ID: 33441311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
    Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
    Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
    Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
    Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
    Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
    Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.